Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Mr. Randy Berholtz
Senior Advisor 
Functionality

Micar Innovation (Micar21) Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.

Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Drug Discovery Collaborations
Headquartner in China
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 939.67KB)
Mr. DIMITAR DIMITROV
LinkedIn logo CEO 
Functionality

MID LABS United States

MID Labs has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, we have been instrumental in revolutionizing the ophthalmic field through our products.

MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Website:
midlabs.com
Company Size (Fulltime employees)
Year of foundation
30
Partnering Objectives
Please specify your partnering goal
marketing partner
Headquartner in China
Medtech Category
Medtech Information 1
Vitrectomy cutter||
Medtech Development Stage
Dr. Kai Chen
CEO 
Functionality

MIMETAS Organ on a chip company Netherlands

High-throughput Human Disease and Tissue Models

MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
Website:
mimetas.com
Company Size (Fulltime employees)
Year of foundation
2013
Please specify your partnering goal
BD collaboration with Pharmas on Preclinical R&D and precision med
Headquartner in China
Your Research Tool and Service name
OrganoPlate - Organ on chip HTS flatform
Service Description
CRO service for OOC platform based HTS. Collaboration on Disease modeling Partnership on Drug discovery Products of OrganoPlate and related instruments
Target client type
Pharmas
Mr. Luc Zhang
VP Great China 
Functionality

Mira Life Science Ventures United States

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Mr. Mel Rothberg
Chairman 
Functionality

MissionBio United States

Single cell multi-omics company to eradicate cancer
Website:
Missionbio.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
To expand user base and market
Headquartner in China
Ms. Yue Wang
Fas 
Functionality

Mito Biopharma United States

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.
Company Size (Fulltime employees)
Year of foundation
2012
Please specify your partnering goal
Development of a drug lead to clinical stage
Headquartner in China
Assets Information 1
MB-W53A|Small molecule NASH IND Lead|NASH|
Assets Information 2
WB-W53B|Small molecule Covid IND lead|Covid-19|
Biotech/Pharma Asset Stage
Dr. "Victor" Shengkan Jin
Founder and CEO 
Functionality

MSA Capital United States

MSA manages over $1.5 billion and invests in global leading early and growth-stage technology-enabled companies.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Invest in startups
Headquartner in China
Dr. Kou Qin
VP 
Functionality

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Mr. Estigarribia Marc
MD 

Mybiogate Inc.

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Lili Jiang